OBJECTIVE: Endothelial nitric oxide synthase (NOS3) activity and cigarette smoking significantly influence endothelial function. We sought to determine whether cigarette smoking modified the association between NOS3 polymorphisms and risk of coronary heart disease or stroke. METHODS: All 1085 incident coronary heart disease cases, all 300 incident ischemic stroke cases, and 1065 reference individuals from the Atherosclerosis Risk in Communities study were genotyped for the T-786C and E298D polymorphisms in NOS3. Using a case-cohort design, associations between genotype/haplotype and disease risk were evaluated by multivariable proportional hazards regression. Multiplicative scale interaction testing evaluated the influence of cigarette smoking history at baseline on these associations. RESULTS: In Caucasians, association between E298D genotype and risk of coronary heart disease was significantly modified by current smoking status (interaction P=0.013), with the highest risk observed in smokers carrying the variant D298 allele relative to nonsmokers carrying two E298 alleles (adjusted hazard rate ratio 2.07, 95% confidence interval 1.39-3.07). In African-Americans, association between T-786C genotype and risk of ischemic stroke was significantly modified by pack-year smoking history (interaction P=0.037), with the highest risk observed in >or=20 pack-year smokers carrying the variant C-786 allele relative to <20 pack-year smokers carrying two T-786 alleles (adjusted hazard rate ratio 4.03, 95% confidence interval 1.54-10.6). CONCLUSIONS: An interaction between the E298D and T-786C polymorphisms in NOS3, cigarette smoking, and risk of incident coronary heart disease and ischemic stroke events appears to exist, suggesting a potential complex interplay between genetic and environmental factors and cardiovascular disease risk.
OBJECTIVE:Endothelial nitric oxide synthase (NOS3) activity and cigarette smoking significantly influence endothelial function. We sought to determine whether cigarette smoking modified the association between NOS3 polymorphisms and risk of coronary heart disease or stroke. METHODS: All 1085 incident coronary heart disease cases, all 300 incident ischemic stroke cases, and 1065 reference individuals from the Atherosclerosis Risk in Communities study were genotyped for the T-786C and E298D polymorphisms in NOS3. Using a case-cohort design, associations between genotype/haplotype and disease risk were evaluated by multivariable proportional hazards regression. Multiplicative scale interaction testing evaluated the influence of cigarette smoking history at baseline on these associations. RESULTS: In Caucasians, association between E298D genotype and risk of coronary heart disease was significantly modified by current smoking status (interaction P=0.013), with the highest risk observed in smokers carrying the variant D298 allele relative to nonsmokers carrying two E298 alleles (adjusted hazard rate ratio 2.07, 95% confidence interval 1.39-3.07). In African-Americans, association between T-786C genotype and risk of ischemic stroke was significantly modified by pack-year smoking history (interaction P=0.037), with the highest risk observed in >or=20 pack-year smokers carrying the variant C-786 allele relative to <20 pack-year smokers carrying two T-786 alleles (adjusted hazard rate ratio 4.03, 95% confidence interval 1.54-10.6). CONCLUSIONS: An interaction between the E298D and T-786C polymorphisms in NOS3, cigarette smoking, and risk of incident coronary heart disease and ischemic stroke events appears to exist, suggesting a potential complex interplay between genetic and environmental factors and cardiovascular disease risk.
Authors: G Sofowora; V Dishy; H G Xie; H Imamura; Y Nishimi; C R Morales; J D Morrow; R B Kim; C M Stein; A J Wood Journal: Pharmacogenetics Date: 2001-12
Authors: Rajat S Barua; John A Ambrose; Sudhesh Srivastava; Mary C DeVoe; Lesley-Jane Eales-Reynolds Journal: Circulation Date: 2003-04-21 Impact factor: 29.690
Authors: Julian P J Halcox; William H Schenke; Gloria Zalos; Rita Mincemoyer; Abhiram Prasad; Myron A Waclawiw; Khaled R A Nour; Arshed A Quyyumi Journal: Circulation Date: 2002-08-06 Impact factor: 29.690
Authors: Paul V Targonski; Piero O Bonetti; Geralyn M Pumper; Stuart T Higano; David R Holmes; Amir Lerman Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: C P M Leeson; A D Hingorani; M J Mullen; N Jeerooburkhan; M Kattenhorn; T J Cole; D P R Muller; A Lucas; S E Humphries; J E Deanfield Journal: Circ Res Date: 2002-06-14 Impact factor: 17.367
Authors: Craig R Lee; Kari E North; Molly S Bray; David J Couper; Gerardo Heiss; Darryl C Zeldin Journal: Pharmacogenet Genomics Date: 2007-05 Impact factor: 2.089
Authors: Adam J Spanier; Robert S Kahn; Richard W Hornung; Ning Wang; Guangyun Sun; Michelle B Lierl; Bruce P Lanphear Journal: Pediatr Pulmonol Date: 2009-08
Authors: Michael A Pacanowski; Issam Zineh; Rhonda M Cooper-Dehoff; Carl J Pepine; Julie A Johnson Journal: Am J Hypertens Date: 2009-04-30 Impact factor: 2.689
Authors: Blazej Misiak; Marta Krolik; Anna Kukowka; Anna Lewera; Przemyslaw Leszczynski; Joanna Stankiewicz-Olczyk; Ryszard Slezak Journal: Int J Endocrinol Date: 2011-11-24 Impact factor: 3.257